- Trials with a EudraCT protocol (30)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
30 result(s) found for: Type III error.
Displaying page 2 of 2.
«
Previous
1
2
EudraCT Number: 2022-000899-19 | Sponsor Protocol Number: EVX-01-001 | Start Date*: 2022-09-16 |
Sponsor Name:Evaxion Biotech A/S | ||
Full Title: An open label, single arm trial evaluating the efficacy and safety of EVX-01 in combination with pembrolizumab in checkpoint inhibitor treatment naïve adults with unresectable or metastatic melanoma | ||
Medical condition: unresectable or metastatic melanoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Trial now transitioned) FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2004-004868-69 | Sponsor Protocol Number: AP7000_1-4002 | Start Date*: 2005-03-07 | |||||||||||
Sponsor Name:ZLB Behring LLC | |||||||||||||
Full Title: Study of Safety and Efficacy of Antihemophilic Factor / von Willebrand Factor Complex (Humate-P®) Using Individualized Dosing in Pediatric and Adult Surgical Subjects with von Willebrand’s Disease | |||||||||||||
Medical condition: Von Willebrand’s disease (VWD) is a common hereditary bleeding disorder. The impaired formation and adhesion of the initial platelet plug is reflected in the prolonged skin bleeding time. In addit... | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004359-57 | Sponsor Protocol Number: CanStem111P | Start Date*: 2017-08-01 | |||||||||||
Sponsor Name:Sumitomo Dainippon Pharma Oncology, Inc. | |||||||||||||
Full Title: A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma. | |||||||||||||
Medical condition: This study will enroll patients with histologically or cytologically confirmed adenocarcinoma of the pancreas that is metastatic (Stage IV). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) NL (Completed) BE (Completed) CZ (Completed) AT (Completed) PT (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005874-11 | Sponsor Protocol Number: 0822-035 | Start Date*: 2009-02-24 | ||||||||||||||||
Sponsor Name:Laboratoires Merck Sharp & Dhome-Chibret | ||||||||||||||||||
Full Title: A Substudy to Explore Biomarkers of Physical Function in the Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of ... | ||||||||||||||||||
Medical condition: This is an exploratory sub-study of Protocol 018 (Eudract N°2007-002693-66) to identify biomarkers of physical function. This biomarker sub-study will use an ongoing clinical study (Protocol 018) ... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Elderly | Gender: Female | |||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-002316-10 | Sponsor Protocol Number: H6Q-MC-S019(b) | Start Date*: 2006-10-09 | |||||||||||
Sponsor Name:Eli Lilly and Company limited | |||||||||||||
Full Title: A Randomized, Phase 2, Placebo-Controlled, Double-Blinded Study With and Without Enzastaurin in Combination With Paclitaxel and Carboplatin as First-Line Treatment, Followed by Maintenance Treatmen... | |||||||||||||
Medical condition: Patients with a histologic diagnosis of FIGO Stage IIB, IIC, III, or IV advanced invasive epithelial ovarian, fallopian tube, or peritoneal carcinoma. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001236-65 | Sponsor Protocol Number: GS-US-312-0119 | Start Date*: 2013-01-15 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia | |||||||||||||
Medical condition: Chronic Lymphocytic Leukemia (CLL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) IE (Completed) GB (Completed) SE (Completed) ES (Completed) DK (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000199-12 | Sponsor Protocol Number: A011-13 | Start Date*: 2022-07-19 | |||||||||||
Sponsor Name:Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and Hig... | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension (PAH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) SE (Prematurely Ended) DE (Trial now transitioned) FR (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) PT (Trial now transitioned) HR (Trial now transitioned) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002463-10 | Sponsor Protocol Number: BLU-667-2303 | Start Date*: 2020-05-28 | ||||||||||||||||
Sponsor Name:Blueprint Medicines Corporation | ||||||||||||||||||
Full Title: A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer | ||||||||||||||||||
Medical condition: RET fusion-positive, Metastatic Non-Small Cell Lung Cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) NO (Trial now transitioned) FI (Completed) BE (Trial now transitioned) DE (Prematurely Ended) PL (Trial now transitioned) CZ (Prematurely Ended) NL (Trial now transitioned) PT (Trial now transitioned) DK (Completed) IT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-002326-11 | Sponsor Protocol Number: ET-C-002-07 | Start Date*: 2008-10-22 | |||||||||||
Sponsor Name:Pharma Mar, S.A. | |||||||||||||
Full Title: A Randomized, Multicenter, Phase III Trial of Trabectedin (Yondelis®) versus Doxorubicin-based Chemotherapy as First-Line Therapy in Patients with Translocation-Related Sarcomas (TRS) | |||||||||||||
Medical condition: Translocation-Related Sarcomas | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) ES (Prematurely Ended) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003686-17 | Sponsor Protocol Number: WiNK | Start Date*: 2020-07-03 | |||||||||||
Sponsor Name:Glycostem Therapeutics BV | |||||||||||||
Full Title: A prospective Phase I/IIa, open-label, multicenter trial to evaluate the safety and efficacy of oNKord®, an off-the-shelf, ex vivo-cultured allogeneic NK cell preparation, in subjects with acute my... | |||||||||||||
Medical condition: acute myeloid leukaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) FR (Completed) NL (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
«
Previous
1
2
